What does target price mean in stocks?
What Is A Target Price In Stocks?
- A target price is an estimate of the future price of a stock. …
- Target prices can be used to evaluate stocks and may be even more useful than an equity analyst’s rating.
- While opinion-based ratings have limited value, target prices can help investors evaluate the potential risk/reward profile of the stock.
What is the price of target stock?
The price target of a stock is the price at which the stock is fairly valued with respect to its historical and projected earnings. When stocks are trading below and above their price targets, investors can maximize their rates of return by buying and selling. Stock price targets are often published by research analysts.
What is target stock price?
The stock has a market cap of $20.58 billion, a price-to-earnings ratio of 875.81, a PEG ratio of 2.71 and a beta of 1.25. ZoomInfo Technologies has a fifty-two week low of $37.86 and a fifty-two week high of $79.17.
What is target share price?
Three of SPXV's underlying holdings with notable upside to their analyst target prices are AMETEK Inc (Symbol: AME), Verisign Inc (Symbol: VRSN), and Trimble Inc (Symbol: TRMB). Although AME has traded at a recent price of $144.06/share, the average ...
Is NKTR a good stock to buy?
Out of 10 analysts, 2 (20%) are recommending NKTR as a Strong Buy, 1 (10%) are recommending NKTR as a Buy, 5 (50%) are recommending NKTR as a Hold, 1 (10%) are recommending NKTR as a Sell, and 1 (10%) are recommending NKTR as a Strong Sell.
Is Nektar a good stock to buy?
Nektar Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.08, and is based on 3 buy ratings, 7 hold ratings, and 2 sell ratings.
Why is Nektar Therapeutics down?
Nektar (ticker: NKTR) shares fell 23.1% on April 18, after the company said that it would end development of its cancer drug called bempeg, following a number of trial failures of the drug in combination with Bristol's (BMY) Opdivo.
Is Nektar public?
18, 2016 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) (" Nektar ") today announced the pricing of its previously announced underwritten public offering of $175.5 million in aggregate gross proceeds, or 13,000,000 shares of its common stock at a public offering price of $13.50 per share.
Will Nktr stock go up?
Nektar Therapeutics (NASDAQ:NKTR) The 8 analysts offering 12-month price forecasts for Nektar Therapeutics have a median target of 4.80, with a high estimate of 6.00 and a low estimate of 3.00. The median estimate represents a +21.67% increase from the last price of 3.95.
What NKTR 214?
Bempegaldesleukin (development code NKTR-214) is an experimental anti-cancer drug candidate. It is a PEGylated interleukin-2 (IL-2) acting as a CD122-preferential IL-2 pathway agonist designed to activate and proliferate CD8+ T cells and NK cells. It is being developed by Nektar Therapeutics.
When did Nektar Therapeutics go public?
May 13, 1994On May 13, 1994 Nektar Therapeutics held their initial public offering (IPO) under the ticker NASDAQ:NKTR.
What Nktr 255?
NKTR-255 is an investigational polyethylene glycol-modified recombinant human IL-15 (rhIL-15) receptor agonist, designed to improve the immunotherapeutic and anti-cancer benefit observed with rhIL-15 while circumventing the toxicities associated with this therapy.
What does Nektar Therapeutics do?
We are focused on creating novel therapies aimed at selectively modulating the immune system to advance the treatment of cancer, autoimmune disorders and chronic inflammatory conditions.
Should I buy or sell Nektar Therapeutics stock right now?
12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nektar Therapeutics in the last year. There are currently 2 sell ratings,...
What is Nektar Therapeutics' stock price forecast for 2022?
12 brokerages have issued 1 year price objectives for Nektar Therapeutics' shares. Their forecasts range from $3.00 to $54.00. On average, they exp...
How has Nektar Therapeutics' stock performed in 2022?
Nektar Therapeutics' stock was trading at $13.51 at the beginning of 2022. Since then, NKTR shares have decreased by 75.4% and is now trading at $3...
When is Nektar Therapeutics' next earnings date?
Nektar Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022. View our earnings forecast for...
How were Nektar Therapeutics' earnings last quarter?
Nektar Therapeutics (NASDAQ:NKTR) released its quarterly earnings data on Thursday, May, 5th. The biopharmaceutical company reported ($0.49) EPS fo...
Who are Nektar Therapeutics' key executives?
Nektar Therapeutics' management team includes the following people: Mr. Howard W. Robin , CEO, Pres & Director (Age 69, Pay $2.14M) Mr. Gilbert...
What is Howard W. Robin's approval rating as Nektar Therapeutics' CEO?
46 employees have rated Nektar Therapeutics CEO Howard W. Robin on Glassdoor.com . Howard W. Robin has an approval rating of 81% among Nektar Ther...
Who are some of Nektar Therapeutics' key competitors?
Some companies that are related to Nektar Therapeutics include Johnson & Johnson (JNJ) , Eli Lilly and (LLY) , Pfizer (PFE) , AbbVie (ABBV) ,...
What other stocks do shareholders of Nektar Therapeutics own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Nektar Therapeutics investors own include Micron Technolog...
When will Nektar Therapeutics release its earnings?
How much does Nektar Therapeutics make?
Nektar Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021. View our earnings forecast for Nektar Therapeutics.
Is Nektar Therapeutics a hold?
How much money does Nektar Therapeutics make? Nektar Therapeutics has a market capitalization of $2.99 billion and generates $152.91 million in revenue each year. The biopharmaceutical company earns $-444,440,000.00 in net income (profit) each year or ($2.24) on an earnings per share basis.
Nasdaq Global Select
Wall Street analysts have given Nektar Therapeutics a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Nektar Therapeutics wasn't one of them.
Environmental, Social, and Governance Rating
A biopharmaceutical company which develops breakthrough products that make a difference in patients lives. It creates differentiated, innovative products by applying its platform technologies to established or novel medicines.
Business Summary
"B" score indicates good relative ESG performance and an above-average degree of transparency in reporting material ESG data publicly and privately. Scores range from AAA to D.
Nektar Therapeutics (NASDAQ:NKTR) Price Target and Consensus Rating
A biopharmaceutical company which develops breakthrough products that make a difference in patients lives. It creates differentiated, innovative products by applying its platform technologies to established or novel medicines.
Analyst Ratings By Month
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy).
Average Share Price and Price Target by Month
The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Nektar Therapeutics (NASDAQ:NKTR) Analyst Ratings Frequently Asked Questions
The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target.
